talkbio – Page 10

Continuous Bioprocessing for Bispecific Antibodies: Innovations Accelerating Therapeutic Antibody Production (2024–2025)

2 weeks ago talkbio0Tagged Antibodies, Bispecific, antibody engineering, Automation, bioprocess, bioprocessing, Continuous, high-throughput, innovation, oncology therapeutics, production, Protein Purification, scale-up, Therapeutic Antibody

continuous bioprocessing; bispecific antibodies; therapeutic antibody production; bioprocess innovation; high-throughput production; antibody engineering; scale-up; oncology therapeutics; protein purification; automation

Biogen Shuffles Staff and Exits AAV Gene Therapy Programs After Strategic Shift

2 weeks ago talkbio0Tagged AAVS1 gene, Biogen, Biotech Layoffs, Discontinuation (procedure), gene therapy, layoffs, Pharma, staff reorganization

Biogen; AAV gene therapy; layoffs; staff reorganization; biotech layoffs; pharma restructuring; gene therapy discontinuation

GSK CEO Emma Walmsley Steps Down After 9 Years; Luke Miels to Succeed

2 weeks ago talkbio0Tagged CEO, Drug Industry, Emma Walmsley, Haleon demerger, Leadership Change, Luke Miels, SmithKline Beecham, specialty medicines, Succession planning, Transition Mutation, Vaccines

Emma Walmsley; GSK; CEO transition; Luke Miels; leadership change; pharmaceutical industry; Haleon demerger; specialty medicines; vaccines; succession planning

New Confirmatory Study Suggests Progress in Applied Therapeutics–FDA Alignment for Rare Disease Drug

2 weeks ago talkbio0Tagged Apply, Clinical Trials, CMT-SORD, confirmatory study, Govorestat, Infrequent, regulatory alignment, United States Food and Drug Administration

Applied Therapeutics; govorestat; CMT-SORD; rare disease; FDA; confirmatory study; clinical trial; regulatory alignment

Sanofi Expands $35 Insulin Program to All U.S. Patients Nationwide

2 weeks ago talkbio0Tagged Affordability, Diabetes, Insulin, Insurance, Medicare, monthly, Programs - Publication Format, sanofi, United States

Sanofi; Insulin; $35 monthly program; Insulins Valyou Savings Program; diabetes; insurance coverage; Medicare; affordability; United States

Eli Lilly’s Oral SERD Inluriyo Approved by FDA for ESR1-Mutated Breast Cancer

3 weeks ago talkbio0Tagged Approved, Carcinoma breast stage IV, Eli, Eli Lilly, EMBER-3 trial, ESR1 gene, Estrogen receptor positive, HER2-negative, Imlunestrant, Inluriyo, Mutation, Oral SERD, United States Food and Drug Administration

Eli Lilly; Inluriyo; oral SERD; imlunestrant; FDA approval; ESR1 mutation; metastatic breast cancer; estrogen receptor positive; HER2-negative; EMBER-3 trial

Trump Administration Teases MFN Drug Pricing Rule as Commitment Deadline Looms for Companies

3 weeks ago talkbio0Tagged Commitment Deadline, direct-to-consumer sales, drug price, executive order, international reference price, Medicaid, MFN, Most-Favored-Nation, Parity, pharmaceutical manufacturers, Prices, Pricing, tariffs, Transplant Registry Unified Management Program

Trump administration; Most-Favored-Nation (MFN) pricing; drug pricing; executive order; pharmaceutical manufacturers; Medicaid; direct-to-consumer sales; price parity; commitment deadline; tariffs; international reference price

Thyme Care Raises $97 Million Series D to Drive AI-Powered Oncology Care at $1B Valuation

3 weeks ago talkbio0Tagged Artificial Intelligence, cancer care, Healthcare technology, oncology ecosystem, orchestration, patient navigation, Series D, strategic investors, Thyme Care, unicorn startup, Value-Based Care

Thyme Care; cancer care; Series D funding; AI orchestration; oncology ecosystem; value-based care; patient navigation; strategic investors; unicorn startup; healthcare technology

Kai Beckmann Appointed as Successor to Merck KGaA CEO Belén Garijo, Effective May 2026

3 weeks ago talkbio0Tagged Belén Garijo, business career, CEO, Corporate, Electronic, Executive Board, governance, Health Care Sector, Kai Beckmann, Leadership Transition, Merck KGaA, strategic transformation, succession

Merck KGaA; Kai Beckmann; Belén Garijo; CEO Succession; Electronics Business; Executive Board; Leadership Transition; Healthcare sector; Corporate governance; Strategic transformation

AstraZeneca Appeals to Supreme Court in Final Attempt to Challenge Medicare Drug Price Negotiation Program

3 weeks ago talkbio0Tagged AstraZeneca, drug price, Farxiga, Inflation Reduction Act, Medicare, Myasthenic Syndromes, Congenital, Negotiation Program, Supreme Court

AstraZeneca; Medicare Drug Price Negotiation Program; Supreme Court; Inflation Reduction Act; Third Circuit; due process; pharmaceuticals; CMS; drug pricing; Farxiga